Similar articles for PMID: 15755994

Year	Number of Results
1971	1
1975	1
1978	1
1981	2
1985	3
1989	1
1990	3
1991	1
1992	2
1993	5
1994	5
1995	5
1996	10
1997	10
1998	13
1999	20
2000	16
2001	14
2002	16
2003	17
2004	21
2005	22
2006	23
2007	14
2008	13
2009	13
2010	11
2011	7
2012	4
2013	4
2014	9
2015	2
2016	4
2017	1
2018	1
2019	1
2020	1
2022	1
2023	1
2024	0

1

Influence of CD80, interleukin-2, and interleukin-7 expression in human renal cell carcinoma on the expansion, function, and survival of tumor-specific CTLs.

Frankenberger B, Pohla H, Noessner E, Willimsky G, Papier B, Pezzutto A, Kopp J, Oberneder R, Blankenstein T, Schendel DJ. Frankenberger B, et al. Clin Cancer Res. 2005 Mar 1;11(5):1733-42. doi: 10.1158/1078-0432.CCR-04-1883. Clin Cancer Res. 2005. PMID: 15755994

2

Efficient generation of autologous peripheral blood-derived cytotoxic T lymphocytes against poorly immunogenic human tumors using recombinant CD80-adenovirus together with interleukin 12 and interleukin 2.

Mogi S, Ebata T, Setoguchi Y, Fujime M, Heike Y, Kohsaka T, Yagita H, Okumura K, Azuma M. Mogi S, et al. Clin Cancer Res. 1998 Mar;4(3):713-20. Clin Cancer Res. 1998. PMID: 9533541

3

Induction of G250-targeted and T-cell-mediated antitumor activity against renal cell carcinoma using a chimeric fusion protein consisting of G250 and granulocyte/monocyte-colony stimulating factor.

Tso CL, Zisman A, Pantuck A, Calilliw R, Hernandez JM, Paik S, Nguyen D, Gitlitz B, Shintaku PI, de Kernion J, Figlin R, Belldegrun A. Tso CL, et al. Cancer Res. 2001 Nov 1;61(21):7925-33. Cancer Res. 2001. PMID: 11691814

4

Superior antitumor in vitro responses of allogeneic matched sibling compared with autologous patient CD8+ T cells.

Kausche S, Wehler T, Schnürer E, Lennerz V, Brenner W, Melchior S, Gröne M, Nonn M, Strand S, Meyer R, Ranieri E, Huber C, Falk CS, Herr W. Kausche S, et al. Cancer Res. 2006 Dec 1;66(23):11447-54. doi: 10.1158/0008-5472.CAN-06-0998. Cancer Res. 2006. PMID: 17145892

5

Expression of B7.1 (CD80) in a renal cell carcinoma line allows expansion of tumor-associated cytotoxic T lymphocytes in the presence of an alloresponse.

Schendel DJ, Frankenberger B, Jantzer P, Cayeux S, Nöbetaner E, Willimsky G, Maget B, Pohla H, Blankenstein T. Schendel DJ, et al. Gene Ther. 2000 Dec;7(23):2007-14. doi: 10.1038/sj.gt.3301349. Gene Ther. 2000. PMID: 11175312

6

Presentation of renal tumor antigens by human dendritic cells activates tumor-infiltrating lymphocytes against autologous tumor: implications for live kidney cancer vaccines.

Mulders P, Tso CL, Gitlitz B, Kaboo R, Hinkel A, Frand S, Kiertscher S, Roth MD, deKernion J, Figlin R, Belldegrun A. Mulders P, et al. Clin Cancer Res. 1999 Feb;5(2):445-54. Clin Cancer Res. 1999. PMID: 10037196

7

T-cell receptor gene-modified T cells with shared renal cell carcinoma specificity for adoptive T-cell therapy.

Leisegang M, Turqueti-Neves A, Engels B, Blankenstein T, Schendel DJ, Uckert W, Noessner E. Leisegang M, et al. Clin Cancer Res. 2010 Apr 15;16(8):2333-43. doi: 10.1158/1078-0432.CCR-09-2897. Epub 2010 Apr 6. Clin Cancer Res. 2010. PMID: 20371691

8

Allogeneic gene-modified tumor cells (RCC-26/IL-7/CD80) as a vaccine in patients with metastatic renal cell cancer: a clinical phase-I study.

Westermann J, Flörcken A, Willimsky G, van Lessen A, Kopp J, Takvorian A, Jöhrens K, Lukowsky A, Schönemann C, Sawitzki B, Pohla H, Frank R, Dörken B, Schendel DJ, Blankenstein T, Pezzutto A. Westermann J, et al. Gene Ther. 2011 Apr;18(4):354-63. doi: 10.1038/gt.2010.143. Epub 2010 Nov 11. Gene Ther. 2011. PMID: 21068778 Clinical Trial.

9

Phase 1 trial of allogeneic gene-modified tumor cell vaccine RCC-26/CD80/IL-2 in patients with metastatic renal cell carcinoma.

Buchner A, Pohla H, Willimsky G, Frankenberger B, Frank R, Baur-Melnyk A, Siebels M, Stief CG, Hofstetter A, Kopp J, Pezzutto A, Blankenstein T, Oberneder R, Schendel DJ. Buchner A, et al. Hum Gene Ther. 2010 Mar;21(3):285-97. doi: 10.1089/hum.2008.192. Hum Gene Ther. 2010. PMID: 19788391 Clinical Trial.

10

Potential of CD80-transfected human breast carcinoma cells to induce peptide-specific T lymphocytes in an allogeneic human histocompatibility leukocyte antigens (HLA)-A2.1+-matched situation.

Meyer GC, Batrla R, Rudy W, Meuer SC, Wallwiener D, Gückel B, Moebius U. Meyer GC, et al. Cancer Gene Ther. 1999 May-Jun;6(3):282-8. doi: 10.1038/sj.cgt.7700054. Cancer Gene Ther. 1999. PMID: 10359214

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

288 results

Results by year